98 results about "Diabetic nephropathy" patented technology

The invention relates to the field of medical information processing and traditional Chinese medicine curative effect evaluation, in particular to a diabetic nephropathy traditional Chinese medicine curative effect evaluation method based on patient report outcome. The method comprises the following steps: searching related symptoms and clinical characterization data of diabetic nephropathy through a medical database, extracting target entries, performing language standardization processing, constructing an initial candidate entry set, calculating the occurrence frequency of each symptom entry, and screening entries meeting a set threshold value to form an entry set; carrying out dimension division on the entry set according to feature attributes to form a preliminary dimension structure set; forming a screening result set through preset logic screening conditions; and carrying out weighted regression fusion on the comprehensive curative effect score and clinical detection data, and outputting a patient curative effect index. In an item weight determination process, dynamic balance between subjective experience and objective statistical information is realized through a mixed weighting model, and the defects of strong subjectivity of expert scoring and large result fluctuation in a traditional method are overcome.

The invention relates to the technical field of medical artificial intelligence diagnosis, and discloses a diabetic nephropathy auxiliary identification method based on multi-source data. The method comprises the following steps: starting a medical data traceability process, capturing original indexes from a multi-heterogeneous system, and arranging the original indexes into an initial data set; and performing hierarchical data fusion according to the pathological evolution knowledge graph to generate a fusion health record with a timestamp. And introducing a dynamic feature weaving process, and extracting a multi-level abnormal feature network from the physiological parameter trajectory according to the priority of the biomarker. And importing the abnormal feature network into a progressive mode learning process, training an identification engine for mapping feature combinations to different disease risk levels, and outputting an identification conclusion by the engine. According to the method, the structured abnormal mode network is constructed through priority-driven dynamic feature weaving, and the recognition engine is trained by using a progressive learning mechanism, so that the accuracy and clinical interpretability of risk stratification of diabetic nephropathy are improved.

The invention relates to the technical field of biological medicine, and discloses an application of an Aspisin small-molecule inhibitor in preparation of a medicine for preventing and / or treating diabetic nephropathy, and the Aspisin small-molecule inhibitor comprises ganoderic acid DM. The inhibitor ganoderic acid DM targeting Aspisin is screened from a bioactive compound library by combining high-throughput virtual drug screening with biological activity screening, it is found that ganoderic acid DM can be specifically combined with Aspisin and shows high affinity, and it is expected that an experimental basis is provided for clinical treatment and prevention of DKD and new drug research and development.

The invention relates to the technical field of molecular biology, in particular to a methylation marker for diagnosis of diabetic nephropathy. Specifically, the methylation marker comprises a P site of a CAT gene promoter region and / or an E site of a CAT gene exon 1 region. Based on a detection system combining methylation sensitive restriction enzyme with quantitative PCR, the kit has the advantages of simplicity and convenience in operation, good repeatability, accuracy in quantification and easiness in standardization, and is suitable for low-invasive samples such as peripheral blood. By effectively distinguishing pure type 2 diabetes patients from diabetic nephropathy combined patients, a reliable technical means is provided for risk stratification, early intervention and dynamic monitoring of diabetic people, and the method has good clinical application prospects and popularization value.

The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.

The invention discloses a biomarker, application of the biomarker in predicting the risk of diabetic nephropathy and a kit, which can realize non-invasive efficient evaluation on the severity of diabetic nephropathy and provide important supplement for early diagnosis and refined risk stratification of diabetic nephropathy. The ratio of the Sulfatase-1 to the creatinine Cr is uSULF1 / Cr, and the Sulfatase-1 and the creatinine Cr are both from urine.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The application discloses a kind of based on multi-source medical text construction traditional Chinese medicine diabetic nephropathy knowledge graph method and system, including following module: data integration module: integration diagnosis and treatment guideline and electronic medical record, after redundancy, terminology standardization constructs unified medical data set;Mixed labeling and entity recognition module: fusion artificial labeling and BERT-BiLSTM-CRF model automatically identifies traditional Chinese medical syndrome, traditional Chinese medicine and other complex entities;Relationship modeling module is based on semantic embedding and multi-label classification algorithm, accurately constructs traditional Chinese and western medicine association rules;Atlas application module: entity relationship is converted into attribute graph structure, supports graph database interactive query, realizes diagnosis and treatment recommendation, contraindication early warning and curative effect analysis.Through the above scheme, the present application significantly improves the accuracy of differentiation, reduces the risk of drug contraindication, provides efficient, interpretable decision support for the prevention and treatment of diabetic nephropathy, has important clinical value and popularization potential.

The invention discloses a tricyclic compound as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and uses of the compound in drugs for treating chronic kidney disease, renal or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing's syndrome, wherein each substituent in the general formula (I) is as defined in the specification.

The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.

The invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof, and relates to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition for treating diabetic nephropathy comprises the following raw materials by weight: 25-35 parts of prepared rehmannia root, 25-35 parts of dogwood, 15-20 parts of Chinese yam, 15-20 parts of oyster, 7-12 parts of Poria cocos and 7-12 parts of white peony root. According to the present invention, the existing decoction-Jiji decoction has a certain alleviating effect on diabetic nephropathy, and further improvement is performed on the basis of the existing decoction formula, such that after the ossa draconis and the radix aconiti lateralis preparata in the original decoction are removed, the reduced pressure reflux extraction under the specific parameters is adopted so as to achieve the effect of treating diabetic nephropathy; the treatment effect of the obtained traditional Chinese medicine composition on diabetic nephropathy can be remarkably improved, a new means is provided for treatment of patients with diabetic nephropathy, and the application prospect is wide.

The present invention relates to a nanoparticle comprising a nanomaterial and at least a first ligand and a second ligand tethered to the nanoparticle. The present invention also relates to a nanoparticle for use as a medicament or diagnostic agent. The present invention also relates to a nanoparticle for use in a method for preventing or treating a disease selected from the group consisting of diabetic nephropathy, glomerulonephritis, glomerular VEGF A dysregulation, endothelial VEGF A dysregulation, diabetic retinopathy, rheumatoid arthritis, age-related macular degeneration and cancer, such as breast cancer. Furthermore, the present invention relates to a method of preparing a nanoparticle.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The invention relates to a double fused ring compound inhibitor as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (III), a preparation method thereof, a pharmaceutical composition containing the compound, and use thereof in the preparation of drugs for treating chronic kidney disease, renal or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing's syndrome.

The invention belongs to the technical field of diabetic nephropathy, and particularly relates to a metabolic risk scoring (MetRS) system for diabetic nephropathy. The diabetic nephropathy metabolism risk scoring system comprises a data acquisition module used for acquiring a metabolic biomarker detection value of a person to be assessed; the risk score calculation module is used for calculating a diabetic nephropathy metabolic risk score of the to-be-evaluated person according to the metabolic biomarker detection value of the to-be-evaluated person; and the risk grade evaluation module is used for evaluating the attack risk of the diabetic nephropathy of the to-be-evaluated person according to the metabolic risk score of the diabetic nephropathy. The method can provide an objective tool for high-risk population identification of diabetic nephropathy, and is of great significance to improvement of diabetic nephropathy management ability and precise prevention and treatment level.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a strain of lactobacillus plantarum capable of improving pancreas islet dysfunction and diabetic nephropathy and application of the lactobacillus plantarum capable of improving pancreas islet dysfunction and diabetic nephropathy. The preservation number of the plant lactobacillus is CGMCC (China General Microbiological Culture Collection Center) No.31657, and the plant lactobacillus is screened from excrement of healthy infants, has excellent acid resistance and cholate resistance, is high in oxidation resistance and reducing capacity, can effectively control the rise of fasting blood-glucose level of diabetic mice and can enhance the glucose tolerance of the diabetic mice; and the protein also has the capabilities of improving pancreas islet functions and regulating insulin resistance and insulin sensitivity. The strain has a wide application prospect in preparation of drugs for relieving or treating pancreas islet dysfunction and diabetic nephropathy.

The invention relates to the technical field of diabetic nephropathy onset risk, in particular to an onset risk prediction method and system for type 2 diabetic nephropathy, and the method comprises the following steps: screening characteristic factors through multi-factor Logistic regression, and obtaining contribution degree through principal component analysis; information centralization and decentralization feature weights are constructed based on the contribution degree, and the game theory is introduced for fusion to obtain the optimal feature weight; and finally, inputting the weighted features into the attention guidance double-current time sequence static fusion network which is deeply fused with the optimal weight, and outputting an onset risk. According to the method, contributions of core and secondary indexes are balanced through the game theory, and deep association of static and dynamic data is mined by using a double-flow network, so that the prediction accuracy is remarkably improved.

The benzyl hydrazine derivative has the advantages of being good in activity and novel in structure, the benzyl hydrazine derivative serves as an RIPK1 small-molecule inhibitor, necroptosis induced by TNF-alpha can be reduced, and therefore the anti-inflammatory effect is achieved, and the benzyl hydrazine derivative can be used for preparing drugs for treating inflammation-related diseases such as diabetic nephropathy.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

The application discloses a research method of a potential protein target point of Guangxi Yaoshan sweet tea against diabetic nephropathy based on proteomics, relates to the technical field of biological medicine, and solves the problem of lacking research on the target point of the action of Yaoshan sweet tea on the prevention and treatment of diabetic nephropathy from the perspective of proteomics. The method comprises the following steps: determining a characteristic active ingredient, namely myricetin, of Yaoshan sweet tea for intervention on diabetic nephropathy, obtaining a PPI network of network pharmacology of the intersection target point of the characteristic active ingredient of Yaoshan sweet tea and diabetic nephropathy; preparing a myricetin solution, preparing a cell disease model and grouping intervention, collecting and pre-treating a cell protein sample, performing mass spectrometry, pre-processing proteomic mass spectrometry data, screening a potential protein target point, identifying and analyzing an expression change trend of the potential protein target point, and analyzing a core protein target point and a key signal path. The application directly locates the key protein target point of Guangxi Yaoshan sweet tea on diabetic nephropathy from a protein expression level, which is more intuitive and more accurate.

The application discloses a chemical structural formula of a biphenyl sulfonamide compound of a bis-benzimidazole, and also discloses application of the compound in preparation of a pharmaceutically acceptable salt or solvate, application of the compound and the pharmaceutically acceptable salt or solvate in preparation of a medicine for treating endothelin-dependent or angiotensin II-dependent diseases. Meanwhile, the biphenyl sulfonamide compound of the bis-benzimidazole can also be used in combination by changing substituted functional groups. The biphenyl sulfonamide compound of the bis-benzimidazole, the prepared pharmaceutically acceptable salt or solvate and the medicine prepared by the compound have pharmacological activities, and have pharmacological effects in animals including human beings, and are particularly useful in treatment or prevention of IgA nephropathy, focal segmental glomerulosclerosis, nephrotic syndrome, chronic kidney disease, diabetic nephropathy, hypertension, coronary heart disease and myocardial infarction.

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives of Formula (I): or a salt or prodrug thereof. These compounds are TLR9 inhibitors useful for the treatment, prevention or slowing of a fibrotic disease, such as liver fibrosis, kidney fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic nephropathy, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.

This invention discloses an optimization method and system for a predictive model of diabetic complications. It involves collecting routine laboratory test data from diabetic patients, performing preprocessing such as missing value removal, label merging, and SMOTE resampling to construct a balanced dataset. The average importance of indicators is evaluated using multiple machine learning models to select a subset of key features. Random forest, XGBoost, support vector machine, and multilayer perceptron are selected as base classifiers, and after hyperparameter optimization, a stacked ensemble learning model is constructed to further improve predictive performance. Finally, the model is packaged as an API service and embedded into a hospital information system to achieve high-precision, low-cost, and real-time risk prediction of diabetic complications. Experimental results show that this invention achieves an accuracy of 98.5% and an AUC of 99.76% in predicting diabetic nephropathy complications, outperforming single models.

The invention provides a diabetic nephropathy glomerular basilar membrane thickness measuring method based on artificial intelligence, and relates to the technical field of basilar membrane thickness measurement, and the method comprises the steps: cutting a diabetic nephropathy glomerular basilar membrane to obtain an input set; utilizing instance feature extraction and attention aggregation to construct a multi-instance learning network; training the multi-instance learning network by using the input set to obtain a trained multi-instance learning network; and analyzing the diabetic nephropathy glomerular basilar membrane by using the trained multi-instance learning network to obtain a basilar membrane thickness measurement result, thereby completing the measurement of the diabetic nephropathy glomerular basilar membrane thickness. The problems that in the prior art, equipment is expensive, operation is complex, and universality is poor are solved.

The invention relates to the technical field of biological medicine, in particular to application of zinc-ginsenoside coordination nano-enzyme in treatment of diabetic nephropathy. The Zn (at) Gs-Re nano-enzyme provided by the invention not only enhances the stability and biological activity of ginsenoside Re, but also endows the ginsenoside Re with novel similar SOD / CAT enzyme activity, realizes multiple synergistic effects of resisting oxidation, resisting inflammation, resisting apoptosis, protecting mitochondria and improving renal functions, and shows remarkable superiority in the aspect of treating diabetic nephropathy and related complications.

The invention provides a traditional Chinese medicine composition for reducing blood sugar and blood fat. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in specific parts by weight: astragalus membranaceus, semen cuscutae, abelmoschus manihot, schisandra chinensis, fructus rosae laevigatae, gordon euryale seed, lumbricus, stiff silkworm, burdock, gallnut, salvia miltiorrhiza, oldenlandia diffusa and the like. Furthermore, the invention provides a preparation and a preparation method of the compound and application of the compound in medicines for preventing or treating hyperlipidemia, diabetes or diabetic nephropathy.

The application discloses an indazole derivative or a pharmaceutical salt thereof and application. The application finds a new indazole derivative, which has an inhibiting function on ROCK kinase, can be used as a ROCK kinase inhibitor, and has a novel structure type, and can be used as a potential therapeutic drug for various diseases, such as inflammatory diseases, autoimmune diseases, fibrotic diseases, transplant rejection, diseases related to excessive secretion of IL-17, IL-21 and / or IL-23, eye diseases, cardiovascular and cerebrovascular diseases, tumor metastasis, central nervous system diseases, diabetic nephropathy and skin diseases, and the like.

The invention relates to a radix astragali and poria cocos kidney-protecting formula, in particular to a radix astragali and poria cocos kidney-protecting formula extract for resisting oxidation and assisting in reducing blood sugar and application of the radix astragali and poria cocos kidney-protecting formula extract. The radix astragali and poria cocos kidney protecting formula extract is applied to preparation of an antioxidant or alpha-glucosidase inhibitor. Although the radix astragali and poria cocos kidney-protecting formula has a treatment effect on diabetic nephropathy, experiments find that the radix astragali and poria cocos kidney-protecting formula is relatively weak in oxidation resistance and relatively weak in alpha-glucosidase inhibition, namely, the hypoglycemic effect is limited. The invention accidentally finds that the ethyl acetate part (QLHSF-EA) of the water extract of the radix astragali and poria cocos kidney-protecting formula has good antioxidant and hypoglycemic activity which is far superior to that of an original formula and a positive control medicine, and a new application of the extract of the radix astragali and poria cocos kidney-protecting formula is developed. The QLHSF-EA can play a role in resisting oxidation by removing DPPH free radicals, and play a role in reducing blood glucose by inhibiting alpha-glucosidase.

The invention discloses a diabetic nephropathy prognosis method, system and device based on an immunofluorescence image, and relates to the technical field of image feature analysis. The method comprises the following steps: acquiring previous immunofluorescence image data of a patient based on disease detection data disclosed by the patient; determining feature change data in the two images of the patient; and importing the characteristic change data in the two images of the patient into the large system model, outputting the predicted re-visit probability and predicted re-visit time point of the patient, and sending an early warning instruction when the single-day data result of the medical institution exceeds the early warning information threshold value of the medical institution. According to the method, for key links in patient prognosis management, the feature change mode associated with prognosis progress in the sequence immunofluorescence image is systematically extracted and quantified. Based on historical and current iconography data of a patient, probabilistic inference is carried out on a re-doctor-seeing demand in a specific time period in the future and an occurrence time node of the re-doctor-seeing demand, and a quantitative risk assessment result and time interval prediction are output.